JP2020505418A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020505418A5 JP2020505418A5 JP2019541246A JP2019541246A JP2020505418A5 JP 2020505418 A5 JP2020505418 A5 JP 2020505418A5 JP 2019541246 A JP2019541246 A JP 2019541246A JP 2019541246 A JP2019541246 A JP 2019541246A JP 2020505418 A5 JP2020505418 A5 JP 2020505418A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- use according
- pathogen
- binding protein
- binds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762452111P | 2017-01-30 | 2017-01-30 | |
| US62/452,111 | 2017-01-30 | ||
| PCT/US2018/016035 WO2018140974A1 (en) | 2017-01-30 | 2018-01-30 | Passive antibody dependent cell-mediated activation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020505418A JP2020505418A (ja) | 2020-02-20 |
| JP2020505418A5 true JP2020505418A5 (enExample) | 2021-03-11 |
Family
ID=62979661
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019541246A Pending JP2020505418A (ja) | 2017-01-30 | 2018-01-30 | 受動抗体依存性細胞媒介活性化 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US11459378B2 (enExample) |
| EP (1) | EP3573640A4 (enExample) |
| JP (1) | JP2020505418A (enExample) |
| CN (1) | CN110536699A (enExample) |
| AU (1) | AU2018213418A1 (enExample) |
| WO (1) | WO2018140974A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019032628A1 (en) | 2017-08-07 | 2019-02-14 | The Regents Of The University Of California | GENERATING PLATFORM FOR SAFE CELLULAR THERAPEUTIC AGENTS |
| CN114206909A (zh) * | 2019-07-21 | 2022-03-18 | 葛兰素史克生物有限公司 | 治疗性病毒疫苗 |
| CN111411079B (zh) * | 2020-03-27 | 2025-12-12 | 北京时合生物科技有限公司 | 细胞培养方法、改造抗体、细胞培养基、细胞产品及其应用 |
| CN114621356A (zh) * | 2022-05-17 | 2022-06-14 | 康希诺生物股份公司 | 以il18为分子佐剂的带状疱疹亚单位疫苗 |
| WO2024086400A1 (en) * | 2022-10-17 | 2024-04-25 | Research Institute At Nationwide Children's Hospital | Macrophage polarizing oncolytic herpes simplex virus for cancer therapy |
| EP4724093A1 (en) * | 2023-06-09 | 2026-04-15 | Cornell University | Vaccines for human cytomegalovirus |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE029465T2 (en) | 2005-08-10 | 2017-02-28 | Macrogenics Inc | Identification and engineering of antibodies with variant Fc regions and methods of using same |
| US9758794B2 (en) * | 2008-04-22 | 2017-09-12 | Rutgers, The State University Of New Jersey | HCV E2 construct compositions and methods |
| MX340971B (es) * | 2009-11-23 | 2016-08-02 | Amgen Inc * | Fragmento cristalizable (fc) de anticuerpo monomerico. |
| EP2603526A1 (en) * | 2010-08-13 | 2013-06-19 | Medimmune Limited | Monomeric polypeptides comprising variant fc regions and methods of use |
| GB201013989D0 (en) * | 2010-08-20 | 2010-10-06 | Univ Southampton | Biological materials and methods of using the same |
| US9676857B2 (en) * | 2012-03-16 | 2017-06-13 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Soluble engineered monomeric Fc |
| CN105669838B (zh) | 2014-12-04 | 2020-10-16 | 厦门大学 | 来自水痘-带状疱疹病毒gE蛋白的中和表位及针对其的抗体 |
-
2018
- 2018-01-30 CN CN201880007963.0A patent/CN110536699A/zh active Pending
- 2018-01-30 JP JP2019541246A patent/JP2020505418A/ja active Pending
- 2018-01-30 WO PCT/US2018/016035 patent/WO2018140974A1/en not_active Ceased
- 2018-01-30 US US16/480,293 patent/US11459378B2/en active Active
- 2018-01-30 EP EP18744927.7A patent/EP3573640A4/en not_active Withdrawn
- 2018-01-30 AU AU2018213418A patent/AU2018213418A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020055858A5 (enExample) | ||
| JP2019519245A5 (enExample) | ||
| Jasinski-Bergner et al. | Molecular mechanisms of human herpes viruses inferring with host immune surveillance | |
| FI3421486T3 (fi) | Uusia vista-ig-rakenteita ja vista-ig:n käyttö autoimmuuni-, allergia- ja tulehdushäiriöiden hoitamiseksi | |
| Couzi et al. | Antibody-dependent anti-cytomegalovirus activity of human γδ T cells expressing CD16 (FcγRIIIa) | |
| Davignon et al. | Modulation of T-cell responses by anti-tumor necrosis factor treatments in rheumatoid arthritis: a review | |
| Jain et al. | Immunotherapy for nasopharyngeal cancer—a review | |
| RU2019102391A (ru) | Доставка терапевтических полипептидов посредством псевдотипированных онкологических вирусов | |
| Johnson et al. | Effector CD4+ T-cell involvement in clearance of infectious herpes simplex virus type 1 from sensory ganglia and spinal cords | |
| Becher et al. | Targeting cytokine networks in neuroinflammatory diseases | |
| US11352428B2 (en) | Modulation of immune response using BTLA agonist antibodies | |
| Poddighe et al. | Biologics for the treatment of juvenile idiopathic arthritis | |
| JP2014516026A5 (enExample) | ||
| JP2016512557A5 (ja) | 二重特異性分子及びそれを用いた方法 | |
| Lorenzo et al. | APL-1, an altered peptide ligand derived from heat-shock protein, alone or combined with methotrexate attenuates murine collagen-induced arthritis | |
| Mitrović et al. | Innate immunity regulates adaptive immune response: lessons learned from studying the interplay between NK and CD8+ T cells during MCMV infection | |
| WO2022006179A1 (en) | Viruses engineered to promote thanotransmission and their use in treating cancer | |
| CN120392995A (zh) | 利用预先存在的微生物免疫的癌症治疗 | |
| Kim et al. | Multivalent DNA vaccine protects against genital herpes by T-cell immune induction in vaginal mucosa | |
| Valenzuela-Cardenas et al. | TNF blockade enhances the efficacy of myxoma virus-based oncolytic virotherapy | |
| Chowdhury et al. | Amino acid differences in glycoproteins B (gB), C (gC), H (gH) and L (gL) are associated with enhanced herpes simplex virus type-1 (McKrae) entry via the paired immunoglobulin-like type-2 receptor α | |
| Jung et al. | Immune control of oncogenic γ-herpesviruses | |
| Leffler et al. | Epstein–Barr virus infection, B‐cell dysfunction and other risk factors converge in gut‐associated lymphoid tissue to drive the immunopathogenesis of multiple sclerosis: a hypothesis | |
| EP3496749B1 (en) | Mhc class ia open conformers | |
| JP2022525535A5 (enExample) |